Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.65 USD | -0.54% | +3.11% | -2.41% |
Evolution of the average Target Price on Fate Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Fate Therapeutics, Inc.
Piper Sandler | |
Wedbush | |
Morgan Stanley | |
BMO Capital | |
Barclays | |
Mizuho Securities | |
Wells Fargo Securities | |
Stifel Nicolaus | |
Cantor Fitzgerald | |
Citigroup | |
HC Wainwright | |
Goldman Sachs | |
EF Hutton | |
BofA Securities | |
SVB Securities LLC | |
Jefferies & Co. | |
SMBC Nikko | |
Cowen | |
Truist Securities | |
Guggenheim | |
Oppenheimer | |
Canaccord Genuity | |
Morgan Lewins & Co. | |
Needham & Co. | |
Baird | |
SVB Leerink |
EPS Revisions
- Stock Market
- Equities
- FATE Stock
- Consensus Fate Therapeutics, Inc.